In contrast to studies suggesting that PERK activation exerts anti-tumor effects, treatment of CRC cells with FAM172A reduced PERK expression and eIf2α phosphorylation, leading to growth inhibition and tumor suppression [48]. The gene discussed is EIF2A; the disease is colorectal carcinoma.